Xarelto Falters Again In ACS Bid, As Competitors Aim To Catch Up To J&J Drug’s Label
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s third rejection of J&J’s attempt to expand use of Xarelto to ACS patients comes as competing oral anticoagulants await agency action on pending applications that could match Xarelto’s breadth of approved indications.
You may also be interested in...
J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.
Janssen made “heroic” efforts to track down vital status for subjects who withdrew from the ATLAS acute coronary syndromes trial, but the data added little to the interpretation of the primary composite endpoint and had a slightly negative effect on all-cause mortality results, FDA advisory committee members said.
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.